# CD4 T-cell subsets

Source: https://onco.cc/terms/cd4-t-cell-subsets/  
OnCo record `cd4-t-cell-subsets` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CD4 T cells can develop different response programmes. Signals, gene activity and measured function help describe a programme; a single marker does not establish what the cell does.

## Summary

CD4 T-cell subsets are differentiation programmes shaped by antigen recognition, cytokines and gene regulation. Conventional naive CD4 cells recognize peptide-HLA class II during priming, often on dendritic cells. Th1, Th2, Th17, follicular helper and regulatory programmes have characteristic signals, transcription factors and outputs, but these are not permanent job titles or mutually exclusive functional tests. The original Th1/Th2 distinction came from mouse clones in 1986; human tissue can contain mixed programmes.

CD4 help can improve the magnitude and quality of a CD8 response. Bennett’s experiments showed that CD40 signalling on antigen-presenting cells could replace CD4 help in a defined cross-priming system. Cella found that CD40 ligation increased dendritic-cell IL-12, ICAM-1, CD80 and CD86 and their T-cell-stimulating capacity. These support one licensing mechanism, not a requirement that every response follows an identical route.

Alspach’s mouse-tumour work required tumour-antigen-specific CD4 and CD8 responses even when the cancer cells lacked class-II molecules; tumour expression of class-II-restricted antigens was needed at the successful rejection site. In Ott’s phase-I melanoma vaccine trial, six people received personal neoantigens. CD4 responses targeted 58 of 97 neoantigens (60%) and CD8 responses 15 (16%). Four of six had no recurrence at 25 months, but the small uncontrolled study did not isolate clinical efficacy.

In untreated human breast tumours, Gu-Trantien found CXCL13-producing Tfh cells mainly in tertiary-lymphoid-structure germinal centres and an eight-gene signature associated with survival or preoperative-chemotherapy response. That is a prognostic association. DeNardo’s mouse mammary-cancer experiments showed a different possibility: IL-4-producing CD4 cells shaped macrophages that promoted invasion and lung metastasis. Subset identity therefore needs tissue, timing and measured-function context.

## Fields

- Kind: Term
- Last checked: 2026-11-11
- Also known as: CD4 subsets; T helper subsets; Th1; Th2; Th17; Tfh; follicular helper T cells

## Notes

- A transcription-factor stain is a clue to a programme, not a function test. In defined human cultures, Tran and colleagues induced high FOXP3 expression without suppressive function. Human colorectal tumours also contained functionally distinct FOXP3-positive populations (Saito 2016). T-bet expression alone does not measure interferon-gamma release, and a bulk Th1-related RNA signature is not a count of one cell type. Neither Th1 nor Th2 identity alone establishes benefit or harm across tissue, timing and tumour contexts.
- How subsets are measured. Flow cytometry can stain transcription factors and, after stimulation, cytokines inside cells; single-cell RNA sequencing assigns programmes by gene expression; tissue staining for CXCL13 or FOXP3 adds location. Each method defines subsets by its own markers, so labels may not match across studies.
- Worked example (inference). A vaccine study reports strong interferon gamma release from CD4 T cells after stimulation with a vaccine peptide, but no CD8 response. That is not necessarily a failure: Th1-like CD4 cells can license dendritic cells and help CD8 responses, and mouse data show CD4 cells are needed for rejection. The result shows a CD4 response under assay conditions; recognition of the tumour and any benefit need separate evidence.
- CD4 does not mean helper-only. Oh and colleagues studied 30,604 T cells from seven bladder-cancer patients and found clonally expanded cytotoxic CD4 states; controlled assays demonstrated MHC-class-II-dependent killing of autologous tumour cells and inhibition by regulatory T cells. This human evidence has a defined cancer, assay and target context. It does not make every CD4 cell cytotoxic or replace the separate helper and regulatory measurements.
- Th1 programmes are associated with IL-12 and interferon-gamma signalling and the transcription factor T-bet. Cells can produce interferon gamma and IL-2 and support macrophage and CD8 responses against intracellular microbes, including the development of memory responses. A T-bet stain alone does not demonstrate any one of those outputs.
- Th2 differentiation in the systems reviewed by Zhu involved IL-4 and IL-2, with GATA3 and characteristic IL-4, IL-5 and IL-13 production. These programmes are studied in parasite and allergic responses. This functional context does not make Th2 identity uniformly harmful or beneficial in a tumour.
- Th17 programmes include ROR-gamma-t and IL-17A, IL-17F and IL-22 outputs. Zhu’s 2010 review described efficient TGF-beta/IL-6-driven differentiation in specified cultures and a later role for IL-23 in development or maintenance. Human STAT3-deficiency observations linked deficient Th17 development with susceptibility to bacterial and fungal infections. Culture steering conditions and barrier-defence associations are not a universal human differentiation recipe or an automatic tumour-effect prediction.
- Follicular helper programmes include BCL6 and the CXCR5 receptor that supports follicular location, and help germinal-centre B cells, including through IL-21. Human breast-tumour Tfh cells can produce CXCL13. Zhu’s 2010 discussion of IL-6/IL-21 culture conditions described uncertainty at that time; neither those conditions nor one marker define every Tfh cell or its function.
- Regulatory programmes help restrain responses and maintain tolerance. FOXP3 is a central regulator, and TGF-beta/IL-2 support induced differentiation in specified experimental systems. IL-10, TGF-beta and CTLA-4-associated interactions can contribute to regulation in context. These are not exclusive outputs of one programme, and the human FOXP3 studies above explain why marker presence needs a separate suppression assay.

## Sources

- Zhu, Yamane and Paul, differentiation of effector CD4 T cell populations (Annu Rev Immunol 2010): https://pubmed.ncbi.nlm.nih.gov/20192806/
- Mosmann et al., two types of murine helper T cell clone: definition according to profiles of lymphokine activities and secreted proteins (J Immunol 1986): https://pubmed.ncbi.nlm.nih.gov/2419430/
- Borst et al., CD4+ T cell help in cancer immunology and immunotherapy (Nat Rev Immunol 2018): https://pubmed.ncbi.nlm.nih.gov/30057419/
- Alspach et al., MHC-II neoantigens shape tumour immunity and response to immunotherapy (Nature 2019): https://pubmed.ncbi.nlm.nih.gov/31645760/
- Ott et al., an immunogenic personal neoantigen vaccine for patients with melanoma (Nature 2017): https://pubmed.ncbi.nlm.nih.gov/28678778/
- Gu-Trantien et al., CD4+ follicular helper T cell infiltration predicts breast cancer survival (J Clin Invest 2013): https://pubmed.ncbi.nlm.nih.gov/23778140/
- DeNardo et al., CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages (Cancer Cell 2009): https://pubmed.ncbi.nlm.nih.gov/19647220/
- Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.: https://pubmed.ncbi.nlm.nih.gov/8760829/
- Help for cytotoxic-T-cell responses is mediated by CD40 signalling.: https://pubmed.ncbi.nlm.nih.gov/9624004/
- Intratumoral CD4<sup>+</sup> T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.: https://pubmed.ncbi.nlm.nih.gov/32497499/
- Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype.: https://pubmed.ncbi.nlm.nih.gov/17644734/
- Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers.: https://pubmed.ncbi.nlm.nih.gov/27111280/
- OpenStax Microbiology, helper T-cell function and differentiation: https://openstax.org/books/microbiology/pages/18-3-t-lymphocytes-and-cellular-immunity

## Connected records

- terms: [Adaptive immune resistance](https://onco.cc/terms/adaptive-immune-resistance/), [Agretopicity](https://onco.cc/terms/agretopicity/), [Neoantigen](https://onco.cc/terms/neoantigen/), [Regulatory T cells](https://onco.cc/terms/regulatory-t-cells/), [T cell](https://onco.cc/terms/t-cell/), [Tertiary lymphoid structures (TLS)](https://onco.cc/terms/tertiary-lymphoid-structures/), [Tumour-associated macrophages (TAMs)](https://onco.cc/terms/tumor-associated-macrophages/), [Tumour-infiltrating lymphocytes (TILs)](https://onco.cc/terms/tils/)
- targets: [CD4](https://onco.cc/targets/cd4/), [CD40](https://onco.cc/targets/cd40/), [CD8](https://onco.cc/targets/cd8/)
- technologies: [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/)
- pathways: [The cancer-immunity cycle](https://onco.cc/pathways/cancer-immunity-cycle/)

---
JSON: https://onco.cc/api/v1/entities/cd4-t-cell-subsets.json